Scarica l'app Stockscreener
0.2267
3.61%
-0.0085
Precedente Chiudi:
$0.2352
Aprire:
$0.2327
Volume 24 ore:
1.32M
Relative Volume:
0.55
Capitalizzazione di mercato:
$30.44M
Reddito:
$1.47M
Utile/perdita netta:
$-23.06M
Rapporto P/E:
-0.9969
EPS:
-0.2274
Flusso di cassa netto:
$-19.64M
1 W Prestazione:
-7.85%
1M Prestazione:
-28.03%
6M Prestazione:
-63.44%
1 anno Prestazione:
-60.55%
Intervallo 1D:
$0.2111
$0.2327
Intervallo di 1 settimana:
$0.2111
$0.2792
Portata 52W:
$0.2111
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Nome
VolitionRX Ltd
Settore
Industria
Telefono
646 650 1351
Indirizzo
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.2267 | 31.58M | 1.47M | -23.06M | -19.64M | -0.2274 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-01 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Iniziato | Maxim Group | Buy |
| 2018-05-14 | Reiterato | The Benchmark Company | Buy |
| 2016-09-07 | Reiterato | Rodman & Renshaw | Buy |
| 2016-02-01 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
VolitionRX Ltd Borsa (VNRX) Ultime notizie
Volume Summary: Is now the right time to enter VolitionRx LimitedJuly 2025 Retail & Step-by-Step Trade Execution Guides - mfd.ru
VolitionRx nears 100 Nu.Q Discover clients, extends reach to Japan - Stock Titan
VolitionRx receives NYSE American non-compliance notice By Investing.com - Investing.com Australia
VolitionRx (VNRX) Plans to Offer Nearly 18 Million Shares - GuruFocus
VolitionRx (VNRX) Faces NYSE American Compliance Challenge - GuruFocus
VolitionRx Gets NYSE American Non-Compliance Notice for Failing Equity Requirements - marketscreener.com
VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VolitionRx stock gets 'below compliance' tag after NYSE warning - Stock Titan
Volume Report: Is VolitionRx Limited affected by consumer sentimentJuly 2025 Earnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
VolitionRx Prepares French Reimbursement Submission for Nu.Q Cancer Blood Tests - MEXC
VolitionRx (VNRX) Moves Forward with French Reimbursement Submis - GuruFocus
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays - Yahoo Finance
Aug Wrap: Is VolitionRx Limited benefiting from innovation trendsMarket Activity Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
VNRX: D. Boral Capital Maintains Buy Rating and $3 Price Target - GuruFocus
VolitionRx (VNRX) Expands Nu.Q Vet Cancer Test Reach in U.S. and Asia - GuruFocus
Dog cancer blood test expands to all 50 states and parts of Asia - Stock Titan
VolitionRX (VNRX) Receives Buy Rating, Price Target Maintained a - GuruFocus
Why VolitionRx Limited stock is popular among millennialsEarnings Growth Report & Expert Curated Trade Setups - Улправда
VolitionRx Signs Amended Securities Purchase Agreement With Lind Global Asset Management XII - TradingView — Track All Markets
Is VolitionRx Limited stock trading near support levels2025 Key Lessons & Growth Oriented Trading Recommendations - Улправда
Volitionrx stock soars after feline cancer test shows high accuracy By Investing.com - Investing.com Nigeria
VolitionRx Limited Announces Breakthrough Clinical Data for Nu.Q Vet Cancer Test in Cats - marketscreener.com
VolitionRx secures $2 million in additional funding through convertible note By Investing.com - Investing.com India
VolitionRX announces breakthrough clinical data for Nu.Q® veterinary cancer test in cats - MarketScreener
VolitionRx secures $2M financing through amended securities agreement; shares up - MSN
VolitionRX Ltd enters amended securities purchase agreement - marketscreener.com
VolitionRx Secures $2.0 Million in Funding - Yahoo Finance
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats - marketscreener.com
A simple blood test that can spot lymphoma in cats may be on the way - Stock Titan
VolitionRx downgraded to Hold from Buy at Maxim - MSN
How buybacks impact VolitionRx Limited stock valueJuly 2025 Update & Entry and Exit Point Strategies - Улправда
How VolitionRx Limited stock performs during Fed tightening cyclesJuly 2025 Pullbacks & Fast Gain Swing Trade Alerts - Улправда
VolitionRX (VNRX) Target Price Slashed by D. Boral Capital | VNR - GuruFocus
Simple blood tests for cancer and sepsis move closer to hospitals in 2025 - Stock Titan
VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment - MSN
VolitionRx to eliminate veterinary CEO role as part of cost-realignment - Investing.com Australia
VolitionRx Announces Termination of CEO Position at Subsidiary - TradingView — Track All Markets
VolitionRx (VNRX) to end Volition Veterinary CEO role, retain Dr. Butera as consultant - Stock Titan
VolitionRx (VNRX) Unveils Innovative Cancer Detection Method - GuruFocus
Volition (NYSE AMERICAN: VNRX) posts 100% sensitivity in 70-person liquid biopsy study - Stock Titan
VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Why VolitionRX Limited stock is a strong buy call2025 Pullback Review & Risk Controlled Daily Plans - Newser
VolitionRx’s Sepsis Biomarker Selected for French National Healthcare Initiative - citybuzz
VolitionRX (VNRX): Analyst Maintains 'Buy' Rating Amidst Stable Price Target | VNRX Stock News - GuruFocus
VolitionRx (NYSE AMERICAN: VNRX) named sole biomarker partner in €6.3M DETECSEPS sepsis detection program - Stock Titan
How VolitionRx Limited stock valuations compare to rivalsGap Up & Fast Entry Momentum Trade Alerts - Newser
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis - Yahoo Finance
VolitionRx (NYSE:VNRX) Lowered to “Hold” Rating by Maxim Group - Defense World
How VolitionRx Limited stock reacts to job market data2025 Market Sentiment & Consistent Growth Equity Picks - Newser
VNRX: Maxim Group Downgrades VolitionRX to Hold | VNRX Stock New - GuruFocus
Healthy Upside Potential: VolitionRX Ltd (VNRX) - Setenews
VolitionRX Ltd Azioni (VNRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):